IKZF1 — patent landscape

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
SCHEMBL61737	0.59	6/20
SCHEMBL68283	0.53	5/20
SCHEMBL60982	0.52	5/20
SCHEMBL677652	0.78	4/20
SCHEMBL68274	0.56	4/20
SCHEMBL69525	0.56	4/20
SCHEMBL62335	0.55	4/20
SCHEMBL61093	0.54	4/20
SCHEMBL70100	0.54	4/20
SCHEMBL62299	0.53	4/20
SCHEMBL62069	0.51	4/20
SCHEMBL69196	0.51	4/20
Formic Acid (SCHEMBL61216)	0.51	4/20
SCHEMBL62936	0.49	4/20
SCHEMBL70131	0.47	4/20
Lenalidomide (SCHEMBL18825)	1.00	3/20
Lenalidomide (SCHEMBL32978)	1.00	3/20
Lenalidomide (SCHEMBL868339)	1.00	3/20
Lenalidomide (SCHEMBL33695)	0.97	3/20
Lenalidomide (SCHEMBL33696)	0.97	3/20

Clinical trials — most relevant to IKZF1 by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
Imatinib Mesylate and Combination Chemotherapy in Treating Patients With Newly Diagnosed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia	PHASE3	ACTIVE_NOT_RECRUITING
A Phase Ib/II Clinical Study Evaluating the Safety and Efficacy of Tislelizumab in Combination With Golidocitinib and Selinexor for the Treatment of R/R NKTCL	PHASE1/PHASE2	RECRUITING
Study of Combination Ruxolitinib and Decitabine Treatment for Accelerated Phase MPN or Post-MPN AML	PHASE1/PHASE2	COMPLETED
Study of Carfilzomib With Irinotecan in Irinotecan-Sensitive Malignancies and Small Cell Lung Cancer Patients	PHASE1/PHASE2	COMPLETED
Safety Study of 5-Azacitidine and Standard Donor Lymphocyte Infusion (DLI) to Treat Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS) Relapsing After Allogeneic Stem Cell Transplantation	PHASE2	COMPLETED
Study of the Beach Regimen on Relapsed/Refractory Acute Myeloid Leukemia (R/R AML)	PHASE2	ACTIVE_NOT_RECRUITING
5-azacytidine Valproic Acid and ATRA in AML and High Risk MDS	PHASE2	COMPLETED
A Study of TQB3820 in Patients With Hematological Malignancies	PHASE1	UNKNOWN
Phase I Dose Finding and Proof-of-concept Study of Panobinostat With Standard Dose Cytarabine and Daunorubicin for Untreated Acute Myeloid Leukemia or Advanced Myelodysplastic Syndrome	PHASE1	COMPLETED
Phase I Study of HeFi-1 to Treat Cancers With CD30 Protein	PHASE1	COMPLETED
Obinutuzumab in Combination With Venetoclax in Previously Untreated Follicular Lymphoma Patients	PHASE1	COMPLETED
A Study of Low-Dose Decitabine in Relapsed or Refractory Acute Lymphocytic Leukemia (ALL)	PHASE1	COMPLETED
Detection of IKZF1 Deletion Mutation in Patients With Acute Lymphoblastic Leukemia and Its Impact in Therapy	nan	UNKNOWN
Prospective Study of Molecular Predictors of Survival in Myelodysplastic Syndromes	nan	COMPLETED
Long Non-coding RNAs and Their Role on Epigenome as Diagnostic Markers in Childhood Acute Lymphoblastic Leukemia of T Cells.	nan	UNKNOWN
RORC Genetic Polymorphism of Rheumatoid Arthritis	nan	COMPLETED
EPIgenetics and in Vivo Resistance of Chronic Myeloid Leukemia Stem Cells to Tyrosine Kinase Inhibitors	nan	UNKNOWN
EKLF Gene Expression in β-thalassemia	nan	NOT_YET_RECRUITING
Studying Genes in Samples From Younger Patients With Relapsed Acute Lymphoblastic Leukemia	nan	COMPLETED
Idarubicin Overcomes MDR1 Induced Chemoresistance With Higher Induction Remission Rate and Quality Than Daunorubicin in Acute Myeloid Leukemia Patients	nan	UNKNOWN
Biomarkers in Blood and Tissue Samples From Patients With Epstein-Barr Virus-Positive Hodgkin Lymphoma	nan	COMPLETED
Novel Biomarkers in Inflammatory Bowel Disease	nan	COMPLETED
Chi-GVM Regimen for the Treatment of R/R PTCL	nan	UNKNOWN
Biochemical Role of Circulating microRNAs Expression as Diagnostic Markers for Non-Hodgkin's Lymphoma Patients	nan	RECRUITING
Molecular Disease Profile of Hematological Malignancies	nan	UNKNOWN
Card14gene (rs34367357 ) Polymorphism in Egyptian Psoriatic and Psoriatic Arthritis Patient	nan	RECRUITING
Molecular and Cellular Characterization of MALT Lymphoma	nan	NOT_YET_RECRUITING
Role of NFKBIA and PTPN22 Genes Polymorphism in Acute Rejection Susceptibility After Living Donor Liver Transplantation in Egyptian Patients.	nan	COMPLETED
Better Delineation of BCL11B Related Phenotype and Epigenetic Signature.	nan	COMPLETED
Cytokine Regulation of Natural Killer Receptors in Inhibiting Activated T Cell Function	nan	UNKNOWN

Related proteins — ESM-2 sequence neighbours (a IKZF1 binder may also engage these)

Protein	Name	Similarity
O13089	—	1.000	O13089 →
P81183	—	1.000	P81183 →
O42410	—	1.000	O42410 →
IKZF2	Zinc finger protein Helios	1.000	landscape →
A2VDW9	—	0.999	A2VDW9 →
Q03267	—	0.998	Q03267 →
Q9H5V7	—	0.997	Q9H5V7 →
Q5R9W9	—	0.997	Q5R9W9 →
IKZF3	Zinc finger protein Aiolos	0.997	landscape →
Q86UP3	—	0.997	Q86UP3 →
O73590	—	0.997	O73590 →
Q9JJN2	—	0.997	Q9JJN2 →
P14404	—	0.997	P14404 →
Q6NRM0	—	0.996	Q6NRM0 →
Q03112	—	0.996	Q03112 →
Q90277	—	0.996	Q90277 →
A0JPB4	—	0.995	A0JPB4 →
Q5ZLR2	—	0.995	Q5ZLR2 →
Q8NAP8	—	0.995	Q8NAP8 →
O08900	—	0.995	O08900 →
A4IFJ6	—	0.995	A4IFJ6 →
P25932	—	0.995	P25932 →
Q8BU00	—	0.995	Q8BU00 →
Q6ZN30	—	0.994	Q6ZN30 →
Q5DTH5	—	0.994	Q5DTH5 →
P57682	—	0.994	P57682 →
Q6DBW0	—	0.994	Q6DBW0 →
Q8BID6	—	0.994	Q8BID6 →
Q2HNT2	—	0.994	Q2HNT2 →
B7ZRU9	—	0.994	B7ZRU9 →